ASLAN Pharmaceuticals appoints Robert Hoffman to its Board as Independent Director

– SINGAPORE, Singapore –  ASLAN Pharmaceuticals (NASDAQ:ASLN | TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, announced today the appointment of Robert E. Hoffman as an Independent Non-Executive Director. Mr. Hoffman has more than 20 years of experience in leading and managing global biotechnology companies, and working with a number of public, late-stage oncology companies.

In planned board changes following ASLAN’s listing on NASDAQ earlier this year, Professor Lai Mei-Shu and Dr. Jerome Shen, who served as Independent Non-Executive Director and Non-Executive Director respectively, will step down from ASLAN’s Board of Directors concurrently.

Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals said:“We are delighted to welcome Robert to ASLAN’s Board of Directors. The depth of his expertise in financial and operational leadership in US-listed biotech companies will be a great asset to ASLAN as we focus on the late-stage development of our clinical programs. On behalf of the Board and management, I would like to thank Professor Lai Mei-Shu and Dr Jerome Shen for their contributions to the growth of the company in the past years. We have benefited immensely from their guidance and insights.”

About Robert Hoffman

Robert E. Hoffman is currently the Chief Financial Officer and Senior Vice President, Finance of Heron Therapeutics, a NASDAQ-listed biotechnology company. Mr. Hoffman has previously served as Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals and was Chief Financial Officer of AnaptysBio. He was part of the founding management team of Arena Pharmaceuticals in 1997 until his departure in 2015 most recently serving as Senior Vice President, Finance and Chief Financial Officer. Robert received his BBA from St. Bonaventure University, and is licensed as a CPA (inactive) in the state of California.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialisation, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>